Follow the people · Insider
Sharon Townson
Sharon Townson files insider transactions with the SEC as a chief scientific officer of Monte Rosa Therapeutics (GLUE). We hold 5 disclosed purchases and sales filed since 2 March 2022, 3 of them in the last 90 days.
- Files forGLUE
- Disclosed buys and sells5 in all, 3 in the last 90 days
- Last disclosure7 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 March 2022 — 6 July 2026Chief Scientific Officer · Monte Rosa Therapeutics (GLUE)24 Form 4 lines · source: SEC Form 4
Everything they disclosed
24 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 6,000 shares of Monte Rosa TherapeuticsSEC Form 47 July 2026Common Stock · traded 6 July 2026 · filed 7 July 2026
- ▼ sold on the open market 5,600 shares of Monte Rosa TherapeuticsSEC Form 47 July 2026Common Stock · traded 6 July 2026 · filed 7 July 2026
- ▼ sold on the open market 400 shares of Monte Rosa TherapeuticsSEC Form 47 July 2026Common Stock · traded 6 July 2026 · filed 7 July 2026
- exercised options over 6,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 47 July 2026Stock Option (Right to Buy) · traded 6 July 2026 · filed 7 July 2026
- exercised options over 3,000 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- ▼ sold on the open market 3,000 shares of Monte Rosa TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- exercised options over 3,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 425 June 2026Stock Option (Right to Buy) · traded 23 June 2026 · filed 25 June 2026
- exercised options over 3,000 shares of Monte Rosa TherapeuticsSEC Form 418 June 2026Common Stock · traded 17 June 2026 · filed 18 June 2026
- ▼ sold on the open market 3,000 shares of Monte Rosa TherapeuticsSEC Form 418 June 2026Common Stock · traded 17 June 2026 · filed 18 June 2026
- exercised options over 3,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 418 June 2026Stock Option (Right to Buy) · traded 17 June 2026 · filed 18 June 2026
- exercised options over 6,000 shares of Monte Rosa TherapeuticsSEC Form 41 June 2026Common Stock · traded 29 May 2026 · filed 1 June 2026
- ▼ sold on the open market 6,000 shares of Monte Rosa TherapeuticsSEC Form 41 June 2026Common Stock · traded 29 May 2026 · filed 1 June 2026
- exercised options over 6,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 41 June 2026Stock Option (Right to Buy) · traded 29 May 2026 · filed 1 June 2026
- was granted 35,000 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 3,155 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 5 January 2026 · filed 5 January 2026
- was granted 158,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 5 January 2026
- was granted 158,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 January 2026Stock Option (Right to Buy) · traded 2 January 2026 · filed 5 January 2026
- was granted 35,000 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 2 January 2026 · filed 5 January 2026
- ▼ sold on the open market 3,155 shares of Monte Rosa TherapeuticsSEC Form 45 January 2026Common Stock · traded 5 January 2026 · filed 5 January 2026
- was granted 161,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 46 January 2025Stock Option (Right to Buy) · traded 2 January 2025 · filed 6 January 2025
- was granted 36,000 shares of Monte Rosa TherapeuticsSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- was granted 40,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 45 June 2024Stock Option (Right to Buy) · traded 3 June 2024 · filed 5 June 2024
- was granted 78,550 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 44 January 2023Stock Option (Right to Buy) · traded 3 January 2023 · filed 4 January 2023
- was granted 70,000 shares of Monte Rosa Therapeutics (a derivative holding)SEC Form 42 March 2022Stock Option (Right to Buy) · traded 1 March 2022 · filed 2 March 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.